Abstract
Brain metastases (BrM) are among the most common neurologic complications of cancer. In fact, up to 40% of patients with a metastatic malignant tumor will develop BrM during their lifetime.1 Historically, patients with BrM have been excluded from clinical trials due to concerns about poor prognosis and increased risk of neurologic toxic effects.2 This has resulted in a scarcity of evidence for the efficacy of systemic therapies in the central nervous system (CNS). Our objective was to determine the proportion of phase 3 clinical trials investigating a systemic therapy intervention for patients with metastatic breast cancer, lung cancer, and melanoma that included patients with BrM and/or evaluated CNS-specific end points.